MoCRA Explained: What Cosmetics Brands Need to Know

6 min read

Why MoCRA Is the Most Important Regulatory Shift Cosmetics Brands Have Faced in a Generation

I've spent more than three decades navigating regulatory environments across industries — Wall Street, healthcare, fintech, enterprise SaaS, and now AI. In that time, I've watched compliance frameworks evolve from afterthoughts to strategic imperatives. The Modernization of Cosmetics Regulation Act, signed into law in December 2022 as part of the Consolidated Appropriations Act, represents exactly that kind of inflection point for the $100+ billion U.S. cosmetics industry. This is not a procedural update. It is a structural reset — and most brands are still treating it like a minor administrative inconvenience.

That's a mistake that will cost them.

In my work with cosmetics and personal care brands, I see the same pattern repeatedly: founders and operators who built successful businesses under decades-old FDA rules suddenly confronting a compliance landscape that looks closer to pharmaceutical regulation than anything they've dealt with before. Understanding what MoCRA actually requires — and why it matters strategically — is the first step toward getting ahead of it.

The Regulatory Baseline Before MoCRA

To appreciate how significant this shift is, you have to understand what preceded it. The Federal Food, Drug, and Cosmetic Act of 1938 governed cosmetics for over 80 years with remarkably minimal requirements. Manufacturers were not required to register their facilities with the FDA. Product formulas did not need to be disclosed. There was no mandatory adverse event reporting. The FDA had limited authority to recall unsafe cosmetic products. Enforcement was largely reactive — the agency could only act after a problem became publicly visible and provably serious.

For brands, this created an environment of relative regulatory freedom. For consumers, it created meaningful gaps in safety oversight. MoCRA closes those gaps — and in doing so, creates significant new operational obligations for every company that manufactures, packages, or distributes cosmetic products in the United States.

What MoCRA Actually Requires: Breaking Down the Core Obligations

There are five primary compliance pillars every brand needs to understand and operationalize:

1. Facility Registration

Every facility that manufactures or processes cosmetic products for distribution in the U.S. must register with the FDA — including foreign facilities. Registrations must be renewed biennially, and any material change to registration information must be updated within 60 days. This applies to contract manufacturers as well, which immediately creates supply chain visibility requirements for brands that outsource production.

2. Product Listing

Responsible parties — typically the brand or domestic distributor — must submit product listings to the FDA for each cosmetic product marketed in the U.S. These listings must include the product name, applicable cosmetic category, ingredients listed in descending order of predominance, and the facility registration number of the manufacturing facility. Listings must be updated annually and whenever product formulations change in a material way.

3. Serious Adverse Event Reporting

This is the requirement that catches brands most off guard. MoCRA mandates that responsible parties submit reports to the FDA within 15 business days of receiving information about a serious adverse event — defined as events resulting in death, disfigurement, hospitalization, disability, or similar serious outcomes. They must also maintain records of all adverse events, including non-serious ones, for six years. For brands without existing pharmacovigilance or complaint management infrastructure, this creates a real operational gap.

4. Safety Substantiation

Responsible parties must maintain records demonstrating that their products are safe for intended use. This does not require FDA pre-approval, but it does require documented, credible safety data that must be available for FDA inspection. This substantiation requirement is the foundation of the entire framework — and the area where documentation practices at many emerging brands are weakest.

5. Labeling Updates

MoCRA introduces new labeling requirements, including mandatory disclosure of fragrance allergens once the FDA finalizes its rulemaking on that specific provision. Brands should be monitoring the FDA's rulemaking calendar closely, because labeling changes require significant lead time across packaging, digital assets, and retail channel compliance.

Where Compliance Programs Break Down in Practice

Facility registration, on its own, is not particularly complex. Most brands get that part done. Where I consistently see compliance programs fracture is in the ongoing, dynamic obligations — specifically the intersection of adverse event tracking, product listing maintenance, and safety substantiation documentation.

The problem isn't awareness of the requirements. It's the absence of systems designed to execute them consistently at scale.

Consider a mid-sized cosmetics brand with 150 SKUs across multiple contract manufacturers. Each formula change, each new product launch, each consumer complaint received through any channel — email, retailer feedback, social media — potentially triggers a compliance obligation. Without automated workflows, most brands are managing this through spreadsheets and manual processes that are inherently fragile. Deadlines get missed. Records become inconsistent. When the FDA sends a records request or inspection notice, the scramble begins.

The six-year record retention requirement for adverse events alone demands a records management infrastructure most growing brands simply haven't built. Add product listing updates, safety substantiation documentation, and biennial registration renewals, and you have a compliance program that requires dedicated operational ownership — not a part-time assignment to someone in the marketing department.

The Strategic Dimension: Compliance as Competitive Advantage

Here is where my perspective as an AI founder and enterprise technology executive informs how I advise brands on this. MoCRA compliance, properly architected, is not just risk mitigation — it is a competitive differentiator.

Retailers increasingly require robust compliance documentation from their cosmetics vendors. Major retail partners are building MoCRA-readiness into their vendor qualification criteria. Brands that can demonstrate audit-ready documentation, rigorous adverse event tracking, and current facility registrations are winning shelf space and vendor agreements that their less-organized competitors are losing.

Beyond the retail channel, consumer trust is increasingly correlated with demonstrated safety transparency. MoCRA compliance gives brands a credible, verifiable foundation for ingredient transparency claims — claims that resonate with the fastest-growing consumer segments in the category.

The brands that will thrive under MoCRA are those that invest in building the right infrastructure now:

Centralized compliance management systems that track registration deadlines, product listing updates, and adverse event reporting obligations in one place
AI-driven document management that maintains safety substantiation records in audit-ready format and flags gaps automatically
Automated adverse event intake workflows that capture consumer complaints across all channels, classify them by severity, and trigger the appropriate response protocols
Regulatory change monitoring that tracks FDA rulemaking — particularly fragrance allergen disclosure timelines — so labeling and formulation decisions are made with current information
Supplier and contract manufacturer integration that keeps facility registration data current as the supply chain evolves

What I Tell Brands That Are Behind

If you're reading this and your MoCRA compliance program is incomplete or inconsistent, the answer is not to panic — it's to prioritize. Start with the obligations that carry the most immediate regulatory and business risk: facility registration verification, adverse event reporting infrastructure, and safety substantiation documentation for your highest-revenue products. Build systematically from there.

The FDA has been measured in its initial enforcement posture as the industry adapts, but that window will not remain open indefinitely. More importantly, your retail partners and institutional customers are not waiting for the FDA. They are asking about your compliance posture today.

MoCRA is not a regulatory inconvenience to be managed around. It is a new operating baseline — one that rewards the brands disciplined enough to build compliance into their operational DNA rather than treating it as a periodic checkbox exercise. In my experience across heavily regulated industries, the companies that win over time are the ones that treat compliance as a core competency, not a cost center.

Build the infrastructure. Document the evidence. Own the process. The brands that do will be positioned to compete at a level their less-prepared competitors simply cannot match.